On March 31, 2026, Skye Bioscience, Inc. announced a repricing of stock options for employees, reducing the exercise price to $0.6150 per share for a total of 2,420,978 options previously priced from $1.055 to $14.56. Additionally, John P. Sharp was appointed as the new Chief Financial Officer effective the same day.